Contribute Try STAT+ Today

Hello, everyone, and how are you today? The sun is shining brightly this morning on the Pharmalot campus, where our official mascot is being escorted by Mrs. Pharmalot on a constitutional, and assorted birds and bugs can be heard in the distance. As for us, we are immersed in our usual routine of foraging for interesting items and brewing cups of stimulation. It is, after all, another busy day. No doubt, it is the same for you. So here are some tidbits to help you along. Hope today proves successful, and keep in touch. …

More than a dozen Republican senators are urging the Biden administration to rescind its “disastrous decision” to support a controversial proposal to temporarily waive intellectual property rights for Covid-19 vaccines, STAT reports. In a harshly worded letter, the lawmakers argued the proposal before the World Trade Organization could hurt the U.S economy and make it easier for other countries, notably China, to steal intellectual property and medical technology.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.